More reads
- Aveo's cancer drug runs into a skeptical FDA. (BioPharma Dive)
- After an unprecedented death, FDA offers few hints for the future of its strategy on fecal transplants. (STAT Plus)
- Obscure model puts a price on good health — and drives down drug costs. (Wall Street Journal)
- She was destined to get early Alzheimer’s, but didn’t. Did a rare mutation protect her? (STAT)
No hay comentarios:
Publicar un comentario